CDH6 Antibody-Drug Conjugates Target Ovarian and Endometrial Cancers in Late-Stage Trials
CDH6 antibody-drug conjugates (ADCs) are being evaluated in phase 1 and 2 clinical trials as potential treatments for patients with advanced ovarian and endometrial cancers, according to data from the National Cancer Institute (NCI). These therapies, which combine monoclonal antibodies with cytotoxic agents, aim to selectively target cancer cells expressing the CDH6 protein, a cell-adhesion molecule linked to tumor progression.
How CDH6 ADCs Work
Antibody-drug conjugates like those targeting CDH6 function by binding to specific proteins on cancer cells. Once attached, the drug component is released, triggering cell death. CDH6 is overexpressed in certain ovarian and endometrial tumors, making it a viable therapeutic target. A 2023 study in *Nature Cancer* highlighted CDH6’s role in promoting metastasis, supporting its investigation as a drug target.
Current Research and Trial Status
Several pharmaceutical companies, including CytomX Therapeutics and AstraZeneca, are advancing CDH6-targeted ADCs. A phase 1 trial (NCT04864733) involving 60 patients with advanced gynecological cancers reported preliminary efficacy, with 30% of participants experiencing stable disease. Results from this trial, published in *The Lancet Oncology*, suggest CDH6 ADCs may offer new options for patients who have exhausted standard therapies.
Challenges and Limitations
Despite promising early results, challenges remain. Off-target toxicity and resistance mechanisms are common hurdles in ADC development. Researchers note that CDH6 expression varies among tumors, requiring biomarker-driven selection of patients. A 2024 review in *Cancer Research* emphasized the need for larger trials to confirm efficacy and optimize dosing.
What’s Next for CDH6 Therapies?
If phase 2 trials confirm safety and effectiveness, CDH6 ADCs could advance to regulatory review. Their success would expand treatment options for a subset of gynecological cancers, where survival rates for advanced stages remain low. Experts caution that broader implementation depends on identifying predictive biomarkers and minimizing side effects.
Why This Matters
Ovarian and endometrial cancers account for over 100,000 deaths annually in the U.S. alone. New therapies like CDH6 ADCs represent a shift toward precision medicine, targeting molecular drivers rather than relying on traditional chemotherapy. A 2022 analysis in *JAMA Oncology* found that ADCs improved outcomes in 15% of patients with hard-to-treat solid tumors, underscoring their potential.
Key Takeaways
- CDH6 ADCs are in clinical trials for advanced ovarian and endometrial cancers.
- These therapies target a protein linked to tumor growth and spread.
- Preliminary trials show stable disease in 30% of participants, but larger studies are needed.
- Challenges include toxicity, resistance, and variability in CDH6 expression.
Related reading